Investors aiming for above-average returns often turn to the practice of stock picking. Skillful choices in individual stocks can be a catalyst for substantial wealth growth.
Akebia Therapeutics Inc (NASDAQ: AKBA) closed the day trading at $3.29 down -0.30% from the previous closing price of $3.3. In other words, the price has decreased by -$0.30 from its previous closing price. On the day, 2.89 million shares were traded. AKBA stock price reached its highest trading level at $3.34 during the session, while it also had its lowest trading level at $3.24.
Ratios:
For a better understanding of AKBA, let’s look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 1.84 and its Current Ratio is at 1.98. In the meantime, Its Debt-to-Equity ratio is 7.21 whereas as Long-Term Debt/Eq ratio is at 6.10.
On April 28, 2025, Leerink Partners started tracking the stock assigning a Outperform rating and target price of $7.
On April 01, 2025, Jefferies started tracking the stock assigning a Buy rating and target price of $6.Jefferies initiated its Buy rating on April 01, 2025, with a $6 target price.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Jun 30 ’25 when Ostrowski Erik sold 41,314 shares for $3.67 per share. The transaction valued at 151,622 led to the insider holds 503,586 shares of the business.
Ostrowski Erik bought 41,314 shares of AKBA for $151,622 on Jun 30 ’25. On Jun 09 ’25, another insider, Malabre Richard C, who serves as the SVP, Chief Accounting Officer of the company, sold 15,000 shares for $4.01 each. As a result, the insider received 60,150 and left with 266,914 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, AKBA now has a Market Capitalization of 872327040 and an Enterprise Value of 933567616. For the stock, the TTM Price-to-Sale (P/S) ratio is 4.28 while its Price-to-Book (P/B) ratio in mrq is 29.61. Its current Enterprise Value per Revenue stands at 4.582 whereas that against EBITDA is 39.985.
Stock Price History:
The Beta on a monthly basis for AKBA is 1.03, which has changed by 1.2847223 over the last 52 weeks, in comparison to a change of 0.16461086 over the same period for the S&P500. Over the past 52 weeks, AKBA has reached a high of $4.08, while it has fallen to a 52-week low of $1.24. The 50-Day Moving Average of the stock is -10.57%, while the 200-Day Moving Average is calculated to be 32.36%.
Shares Statistics:
Over the past 3-months, AKBA traded about 4.79M shares per day on average, while over the past 10 days, AKBA traded about 4611460 shares per day. A total of 263.04M shares are outstanding, with a floating share count of 254.02M. Insiders hold about 4.19% of the company’s shares, while institutions hold 39.88% stake in the company. Shares short for AKBA as of 1753920000 were 24538006 with a Short Ratio of 5.12, compared to 1751241600 on 25504822. Therefore, it implies a Short% of Shares Outstanding of 24538006 and a Short% of Float of 9.43.
